A fresh preparation of BCG (Istituto Vaccinogeno Antitubercolare, Milano) having a bacterial charge of 0.5 mg/ml was injected intranodularly in cutaneous and subcutaneous metastases of malignant melanoma of 22 patients. A total of 85 nodules were treated. Caseous necrosis was observed in 17 patients equal to 68 nodules. The side-effects were modest and cleared up in a short time. The results obtained were localized at the treated nodules, without giving rise to a therapeutic action on those not injcted. The evolution of the disease was not modified.
Get full access to this article
View all access options for this article.
References
1.
BaldwinR. W., PimmM. V.: BCG immunotherapy of pulmonary growths from intravenously transferred rat tumor cells.Brit. J. Cancer,27: 48, 1973.
2.
BaldwinR. W., PimmM. W.: BCG immunotherapy of local subcutaneous growths and post-surgical pulmonary metastases of a transplanted rat epithelioma of spontaneous origin.Int. J. Cancer, 12: 420–427, 1973.
3.
CarterS. K., FriedmanM. A.: A new antitumor agent with activity against malignant melanoma.5-(3-3 dimethyl-1-triazeno) imidazole-4-carboxamide (DTIC, DIC, NSC, 45388). Europ. J. Cancer, 8: 85–92, 1972.
4.
FossatiG., ColnaghiM. I., Della PortaG., CascinelliN., VeronesiU.: Cellular and humoral immunity against human malignant melanoma.Int. J. Cancer, 8: 344–350, 1971.
5.
HellstromK. E., HellstromI.: Immunity to neuroblastomas and melanomas.Annals Radium Medicine, 23: 19–38, 1972.
6.
Int. Group for the Clinical Study of Melanoma:Preliminary report on the trial with combination chemiotherapy.Proc. Scientific Meeting, Oslo, 13–15 giugno 1973.
7.
MathéG., AmielJ. L., SchwarzenbergL., SchneiderM., CattanA., SchlumbergerJ. R., MayatM., De VassalF.: Active immunotherapy for acute lymphoblastic leukemia.Lancet, I: 697–699, 1969.
8.
MathéG.: Immunological treatment of leukemias.Brit. Med. J., 487–488, 1970.
9.
MortonO. L., EilberR. F., MalmgrenR. A., WoodW. C.: Immunological factors which influence response to immunotherapy in malignant melanoma.Surgery, 68: 158–164, 1970.
10.
MortonD. L., EilbertR. F., JosephW. L., WoodW. C., TrahamE., KetchamA. S.: Immunological factors in human sarcomas, and melanomas, a rational basis for immunotherapy.Ann. Surg., 172: 740–749, 1970.
11.
MathansonL.: Regression of intradermal malignant melanoma after intralesional injectio of mycrobacterium bovis strain BCG.Cancer Chemiother., 56: 659–665, 1972.
12.
PinskyC., MirschantV., AlltgenH.: Treatment of malignant melanoma by intratumoral injection of BCG.Proc. Am. Ass. Cancer Res.,13: 21, 1972.
13.
ZbarB., BernsteinI. D., RappM. J.: Suppression of tumor growth at the site of infection with living bacillus Calmette-Guerin.J. Nat. Cancer Inst., 46: 831–839, 1971.
